For the quarter ending 2026-03-31, ALMS had -$25,780K decrease in cash & cash equivalents over the period. -$87,246K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -93,053 | -92,931 | -110,752 | -39,642 |
| Stock-based compensation | 12,339 | 8,107 | 9,787 | 25,630 |
| Net accretion of discounts on marketable securities | -1,961 | -1,422 | -1,724 | -2,152 |
| Depreciation and amortization | 871 | 867 | 916 | 1,713 |
| Gain on bargain purchase in connection with the acelyrin merger | - | 0 | 0 | 187,907 |
| Non-cash lease expense | 575 | 540 | 537 | 624 |
| Impairment of long-lived assets | 444 | 0 | 529 | - |
| Research and development prepaid expenses | 436 | -2,047 | -2,053 | -7,373 |
| Other liabilities, non-current | - | 39 | 0 | 168 |
| Other prepaid expenses and other assets | -780 | -3,883 | -13,250 | -96 |
| Other assets, non-current | 545 | 462 | 3,350 | 1,723 |
| Deferred income tax liability | - | 0 | 0 | 8,561 |
| Accounts payable | 1,432 | 5,550 | -10,424 | -1,162 |
| Deferred revenue | 2,259 | 2,125 | -667 | 2,611 |
| Research and development accrued expenses | 1,178 | -2,848 | -6,102 | 11,037 |
| Other accrued expenses and current liabilities | -9,716 | 3,482 | -3,983 | 6,537 |
| Operating lease liabilities | -1,249 | -884 | -979 | -1,349 |
| Net cash used in operating activities | -87,082 | -71,907 | -110,909 | -186,707 |
| Maturities of marketable securities | 142,862 | 142,532 | 161,149 | 144,274 |
| Purchases of marketable securities | 428,384 | 47,519 | 137,113 | 24,535 |
| Purchases of property and equipment | 164 | 0 | 0 | 653 |
| Cash, cash equivalents and restricted cash acquired in connection with the acelyrin merger | - | 0 | 0 | 49,742 |
| Net cash (used in) provided by investing activities | -285,686 | 95,013 | 24,036 | 168,828 |
| Proceeds from public offering of common stock, net of underwriter discounts, commissions and offering costs | 323,797 | - | - | - |
| Proceeds from issuance of common stock upon exercise of stock options | 23,191 | 489 | - | - |
| Repurchase of common stock shares issued upon early exercised restricted common stock | - | 0 | 0 | 17 |
| Proceeds from issuance of common stock under the 2024 espp | - | 829 | 0 | 766 |
| Net cash provided by financing activities | 346,988 | 1,318 | 0 | 749 |
| Net decrease in cash, cash equivalents and restricted cash | -25,780 | 24,424 | -86,873 | -17,130 |
| Cash, cash equivalents and restricted cash at beginning of period | 91,053 | 66,629 | 170,632 | - |
| Cash, cash equivalents and restricted cash at end of period | 65,273 | 91,053 | 66,629 | - |
ALUMIS INC. (ALMS)
ALUMIS INC. (ALMS)